Literature DB >> 22363920

Role of HbA1c in the Screening of Diabetes Mellitus in a Korean Rural Community.

Jae Hyun Kim1, Gun Woo Kim, Mi Young Lee, Jang Yel Shin, Young Goo Shin, Sang Baek Koh, Choon Hee Chung.   

Abstract

BACKGROUND: Recently, the measurement of glycated hemoglobin (HbA1c) was recommended as an alternative to fasting plasma glucose or oral glucose tolerance tests for diagnosing diabetes mellitus (DM). In this study, we analyzed HbA1c levels for diabetes mellitus screening in a Korean rural population.
METHODS: We analyzed data from 10,111 subjects from a Korean Rural Genomic Cohort study and generated a receiver operating characteristic curve to determine an appropriate HbA1c cutoff value for diabetes.
RESULTS: The mean age of the subjects was 56.3±8.1 years. Fasting plasma glucose and 2-hour plasma glucose after 75 g oral glucose tolerance tests were 97.5±25.6 and 138.3±67.1 mg/dL, respectively. The mean HbA1c level of the subjects was 5.7±0.9%. There were 8,809 non-DM patients (87.1%) and 1,302 DM patients (12.9%). A positive relationship between HbA1c and plasma glucose levels and between HbA1c and 2-hour plasma glucose levels after oral glucose tolerance tests was found in a scatter plot of the data. Using Youden's index, the proper cutoff level of HbA1c for diabetes mellitus screening was 5.95% (sensitivity, 77%; specificity, 89.4%).
CONCLUSION: Our results suggest that the optimal HbA1c level for DM screening is 5.95%.

Entities:  

Keywords:  Diabetes mellitus; Diagnosis; Hemoglobin A, glycosylated; Screening

Year:  2012        PMID: 22363920      PMCID: PMC3283825          DOI: 10.4093/dmj.2012.36.1.37

Source DB:  PubMed          Journal:  Diabetes Metab J        ISSN: 2233-6079            Impact factor:   5.376


  25 in total

1.  Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population.

Authors:  C L Rohlfing; R R Little; H M Wiedmeyer; J D England; R Madsen; M I Harris; K M Flegal; M S Eberhardt; D E Goldstein
Journal:  Diabetes Care       Date:  2000-02       Impact factor: 19.112

2.  Consequences of bias and imprecision in measurements of glucose and hba1c for the diagnosis and prognosis of diabetes mellitus.

Authors:  Per Hyltoft Petersen; Lone G M Jørgensen; Ivan Brandslund; Niels De Fine Olivarius; Marta Stahl
Journal:  Scand J Clin Lab Invest Suppl       Date:  2005

3.  Utility of A1C for diabetes screening in the 1999 2004 NHANES population.

Authors:  Catherine Buell; Duclie Kermah; Mayer B Davidson
Journal:  Diabetes Care       Date:  2007-06-11       Impact factor: 19.112

4.  Is the measurement of glycated hemoglobin A1c alone an efficient screening test for undiagnosed diabetes? Japan National Diabetes Survey.

Authors:  Tomoko Nakagami; Makoto Tominaga; Rimei Nishimura; Nobuo Yoshiike; Makoto Daimon; Toshihide Oizumi; Naoko Tajima
Journal:  Diabetes Res Clin Pract       Date:  2006-10-17       Impact factor: 5.602

5.  The relationship between glycosylated haemoglobin levels and various degrees of glucose intolerance.

Authors:  A Verrillo; A de Teresa; R Golia; V Nunziata
Journal:  Diabetologia       Date:  1983-05       Impact factor: 10.122

6.  The national glycohemoglobin standardization program: a five-year progress report.

Authors:  R R Little; C L Rohlfing; H M Wiedmeyer; G L Myers; D B Sacks; D E Goldstein
Journal:  Clin Chem       Date:  2001-11       Impact factor: 8.327

7.  Mean blood glucose and biological variation have greater influence on HbA1c levels than glucose instability: an analysis of data from the Diabetes Control and Complications Trial.

Authors:  Robert J McCarter; James M Hempe; Stuart A Chalew
Journal:  Diabetes Care       Date:  2006-02       Impact factor: 19.112

8.  Value of hemoglobin A1c in diagnosing diabetes mellitus within a chronic disease management system illustrated by the receiver operating characteristic curve.

Authors:  Wael E Eid; James V Pottala
Journal:  Endocr Pract       Date:  2010 Jan-Feb       Impact factor: 3.443

9.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program.

Authors:  William H Herman; Yong Ma; Gabriel Uwaifo; Steven Haffner; Steven E Kahn; Edward S Horton; John M Lachin; Maria G Montez; Tina Brenneman; Elizabeth Barrett-Connor
Journal:  Diabetes Care       Date:  2007-05-29       Impact factor: 19.112

View more
  4 in total

1.  Diagnostic efficiency of hemoglobin A1c for newly diagnosed diabetes and prediabetes in community-based Chinese adults aged 40 years or older.

Authors:  Kai Liang; Yu Sun; Wen-juan Li; Xiu-ping Zhang; Cheng-qiao Li; Wei-fang Yang; Ze-qiang Ma; Ai-xia Ma; Hui-zhen Zheng; Jun Song; Peng Lin; Xin-guo Hou; Li Chen
Journal:  Diabetes Technol Ther       Date:  2014-07-11       Impact factor: 6.118

2.  Additional perspectives on chronic kidney disease of unknown aetiology (CKDu) in Sri Lanka--lessons learned from the WHO CKDu population prevalence study.

Authors:  Jennifer Hoponick Redmon; Myles F Elledge; Donna S Womack; Rajitha Wickremashinghe; Kamani P Wanigasuriya; Roshini J Peiris-John; Joseph Lunyera; Kristin Smith; James H Raymer; Keith E Levine
Journal:  BMC Nephrol       Date:  2014-07-28       Impact factor: 2.388

3.  A Novel Earwax Method to Measure Acute and Chronic Glucose Levels.

Authors:  Andrés Herane-Vives; Susana Espinoza; Rodrigo Sandoval; Lorena Ortega; Luis Alameda; Allan H Young; Danilo Arnone; Alexander Hayes; Jan Benöhr
Journal:  Diagnostics (Basel)       Date:  2020-12-10

4.  The relationship between BMI and glycated albumin to glycated hemoglobin (GA/A1c) ratio according to glucose tolerance status.

Authors:  Ji Hye Huh; Kwang Joon Kim; Byung-Wan Lee; Dong Wook Kim; Eun Seok Kang; Bong Soo Cha; Hyun Chul Lee
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.